ClinicaliQ Trial Snapshot
- To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva — Recruiting • Phase II • NCT05090891.
- A drug called INCB000928 is tested against placebo in patients with fibrodysplasia ossificans progressiva to assess its effectiveness and safety.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This Phase 2, Randomized, Double-Blind, Placebo-Controlled Study is intended to evaluate the Efficacy, Safety, and Tolerability and PK of INCB000928 administered to participants with a clinical diagnosis of fibrodysplasia ossificans progressiva (FOP). Conditions: Fibrodysplasia Ossificans Progressiva (FOP) Interventions: INCB000928, Placebo Lead Sponsor: Incyte Corporation Planned Enrollment: 98 participants